pharmaceutical investing Johnson & Johnson announces new data showing TREMFYA® is the only IL-23 to deliver durable fistula remission through 48 weeks in Crohn's disease with perianal fistula
pharmaceutical investing AbbVie Presents Data for ABBV-466, a Novel Dual-Targeting Therapy Demonstrating Higher Endoscopic Remission Rates Than Either Anti-IL-23 or Anti-?4?7 Monotherapy in Moderate to Severe Crohn's Disease
pharmaceutical investing AbbVie to Present Data at the 2026 European Society for Medical Oncology Congress Highlighting Progress Across its Expanding Solid Tumor Portfolio
pharmaceutical investing SKYRIZI® and RINVOQ® Data Highlight Long-Term Clinical and Endoscopic Outcomes Across Inflammatory Bowel Disease at UEGW 2026
pharmaceutical investing Pfizer Showcases Clinical Advancements Across Infectious Diseases at IDWeek 2026
pharmaceutical investing AbbVie Presents New Phase 3 AFFIRM Data Showing Clinical and Endoscopic Outcomes With Subcutaneous SKYRIZI® in Patients With Moderately to Severely Active Crohn's Disease
pharmaceutical investing TREMFYA® demonstrated sustained clinical and endoscopic remission through 3 years in moderately to severely active Crohn's disease
pharmaceutical investing New TREMFYA® study shows consistent perianal fistula remission across key Crohn's disease patient subgroups
pharmaceutical investing New SKYRIZI® and RINVOQ® Data Demonstrate Disease Control for Patients Living With Inflammatory Bowel Disease
pharmaceutical investing New Johnson & Johnson ICOTYDE® long-term data demonstrate robust 2-year results in the treatment of adults and adolescents with plaque psoriasis
pharmaceutical investing Pfizer's TUKYSA Regimen Receives FDA Approval as Front-Line Maintenance Treatment for HER2+ Metastatic Breast Cancer
Brixton Metals Reports 97.0% Gold Recovery in Initial Metallurgical Work from the Trapper Gold Target
GoldInxs Commences Maiden Drill Program at the Fishpot Project, Testing Multiple Gold-Silver and Copper-Gold Targets
